Thursday, 22 October 2026
Broader PBS access for ADHD, NSW expands GP ADHD authority, US approves hepatitis B regimen
- 01
PBAC backs broader PBS access to non-stimulant ADHD medicines
The PBAC has recommended broader PBS access to atomoxetine and guanfacine and expanding authorised prescribers beyond specialists for treatment initiation. The proposed restrictions would allow subsidised use in patients who tolerated but did not adequately respond to stimulant therapy, while retaining both medicines as second-line options. The committee said the changes would align PBS access with contemporary Australian clinical guidelines and broaden access where stimulants were ineffective or clinically inappropriate. It considered the changes likely to offer acceptable value for money despite cost-effectiveness not being formally established and uncertainty about the untreated population. The PBAC supported monitoring utilisation and prescribing patterns after implementation, with further work planned on PBS-listed stimulant medicines for ADHD.
via RACGP newsGP
- 02
Nearly 300 NSW GPs gain ADHD diagnostic and prescribing authority
Nearly 300 NSW GPs can now diagnose and treat ADHD and prescribe medication after completing endorsed prescriber training, with regional and remote communities prioritised. A further 300 GPs were expected to begin training from November, while specialist psychiatrists and paediatricians would provide support through the Virtual Psychiatry Hub and Sydney Children’s Hospitals Network. The expansion followed reforms that have trained more than 1,675 GPs to write continuation prescriptions for ADHD medication since September 2025. Rural Doctors Association of NSW president Dr Rachel Christmas welcomed the improved access but said the arduous training and existing workloads could limit uptake, particularly in rural areas. A separate $1.5 million program funding up to 25,000 bulk-billed ADHD assessments is due to start in early 2027.
- 03
FDA approves first-in-class Hibsago regimen for chronic hepatitis B
The US Food and Drug Administration approved Hibsago alongside standard antivirals for certain adults with chronic hepatitis B who have not developed cirrhosis. Eligible patients must have received antivirals for at least six months, have suppressed blood levels of hepatitis B virus and low levels of a protein indicating active infection. The RNA-based treatment is given by periodic injection over six months and is intended to provide a potential “functional cure” by blocking viral replication and stimulating an immune response. In two late-stage studies, Hibsago plus antivirals cleared the virus in about one-fifth of recipients, compared with none receiving placebo plus antivirals. The label warns of sudden increases in liver inflammation or enzyme levels and low platelet counts, with the FDA recommending weekly or bi-weekly laboratory testing.
via BioPharma Dive
- 04
WA voluntary assisted dying demand outpaces service capacity
Demand for voluntary assisted dying in Western Australia grew faster than staffing and operational capacity in 2025–26, with 1249 first requests, up 21% from the previous year. Of 172 health practitioners eligible to participate, GPs comprised almost half, and most participating practitioners cared for two to 10 patients. A total of 541 people died after choosing VAD, representing 2.9% of deaths in WA, while 27.6% of VAD patients lived in regional areas. The WA Voluntary Assisted Dying Board said delays in the statewide care navigator service could contribute to further suffering or reduced access to end-of-life choices. It called for MBS items for assisted dying services, removal of Commonwealth restrictions on telehealth and electronic communication, and WA law changes allowing care transfers between trained practitioners.
- 05
England tightens restrictions on high-risk cosmetic procedures
England will restrict high-risk cosmetic procedures including liquid Brazilian butt lifts, vampire facials and chemical peels to certain healthcare professionals. The government also announced an under-18 ban on cosmetic surgery and other high-risk procedures, while NHS procedures used to treat medical conditions may remain available case by case. Providers who break the rules will face new criminal offences, unlimited fines or fixed penalties of up to £4000. The Department of Health and Social Care said the measures would close a dangerous loophole and target rogue providers putting patients at risk.
via BMJ
- 06
Brepocitinib succeeds in two phase 3 uveitis trials
Brepocitinib met study goals in two phase 3 trials involving patients with non-infectious uveitis, a condition that can lead to blindness. In Clarity-1 and Clarity-2, patients receiving the drug had a median time to treatment failure of more than 48 weeks, compared with 12 weeks for placebo recipients. Treated patients also went 40 weeks without requiring immunosuppressive steroids, and the drug met every secondary endpoint, including resolution of macular oedema, Priovant Therapeutics said. The company plans to submit a supplemental application in the first half of next year to expand brepocitinib’s approved use beyond adult dermatomyositis.
via BioPharma Dive
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.